Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro.

In vitro effects of docetaxel on the human colon carcinoma cell line HT-29 were studied with respect to the expression of different adhesion and surface marker molecules, the adhesion and immunocytotoxicity of peripheral blood lymphocytes and the secretion of IFN-gamma and TNF-alpha. Docetaxel, in a low concentration range (1-3x10-9 M), increased the expression of the adhesion molecules LFA-3, ICAM-1, CD44s, CD44v6, CD15, CD13 and VLA-4/5/6 on the tumor cells. Unstimulated and interleukin-2 (IL-2) activated killer (LAK) cells showed a better adherence to docetaxel treated HT-29 cells than to untreated cells. In neutralization experiments, anti-LFA-3, -CD44v6, -CD15, -VLA -4 and anti-CD13 mAb reduced the lymphocyte adhesion to untreated and docetaxel treated cells at different degrees, while CEA mAb increased the adhesion. Unstimulated and IL-2 activated lymphocytes exhibited significantly higher cytotoxicities against docetaxel treated cells than against untreated HT-29 cells. Unstimulated and IL-2 stimulated lymphocytes secreted more TNF-alpha and IFN-gamma when cocultured with docetaxel treated HT-29 cells than with untreated cells. These results suggest, that the increased lymphocyte mediated cytotoxicity against docetaxel treated HT-29 colon carcinoma cells may reflect an immunological process coupled with induction of differentiation, that may contribute to the clinically known cytostatic effects of the drug.